Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Enrollment has begun in Sagent"s CAMostat Efficacy vs. pLacebo for Outpatient Treatment of COVID-19, a multicenter, randomized, double-blind, placebo-controlled Phase II trial of the clinical efficacy of Camostat in ambulatory subjects with confirmed COVID–19.
Lead Product(s): Camostat
Therapeutic Area: Infections and Infectious Diseases Product Name: Foipan
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020